삼성바이오로직스, 실적 좋은데 목표가는 ‘뚝’…이유는 ‘현금 흐름’
Samsung Securities lowered Samsung Biologics' target price from 2.2 million won to 2.1 million won on the 23rd, citing a decrease in net cash flow, despite good profitability leverage, securing a US base, and modality diversification.
Key takeaway
"삼성바이오로직스, 실적 좋은데 목표가는 ‘뚝’…이유는 ‘현금 흐름’" — BullBear's AI rates this story as a mixed, direction-neutral signal, with a market-impact score of 10 out of 100. Samsung Securities lowered Samsung Biologics' target price from 2.2 million won to 2.1 million won on the 23rd, citing a decrease in net cash flow, despite good profitability leverage, securing a US base, and modality diversification. Reported by Maeil Business on April 22, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Get the next high-impact catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 53.3%.